Çocuklarda santral sinir sisteminin inflamatuvar demiyelinizan hastalıklarının değerlendirilmesi
Yükleniyor...
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Necmettin Erbakan Üniversitesi Meram Tıp Fakültesi
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Amaç: Çalışmamızda otolog kök hücre nakli (OKHN) yapılmış olan hematolojik maligniteli hastaların engrafman sürelerini ve hastalıksız sağ kalım sürelerini (HSS) değerlendirmeyi ve kliniğimizin sonuçlarını literatür ile karşılaştırmayı amaçladık.
Yöntem: Aralık 2011-Aralık 2020 tarihleri arasında Necmettin Erbakan Üniversitesi Hematoloji Bilim Dalında yapılan toplam 113 otolog kök hücre nakli retrospektif olarak hasta kayıt arşiv dosyaları ve hastane bilgi yönetim sistemi üzerinden incelendi. Verilerin analizinde IBM SPSS (v 20.0) kullanıldı.
Bulgular: 84 (%74,3) Multiple myelom (MM), 19 (%16,8) non hodgkin lenfoma (NHL), 8 (%7,1) hodgkin lenfoma (HL), 1(%0,9) akut miyeloid lösemi (AML) ve 1(%0,9) T-lenfoblastik lenfoma (T-LBL) hastamız vardı. Hastaların %45,1 kadın, %54,9 erkek idi. Ortanca nötrofil engrafman günü 11 (9-14), trombosit engrafman günü 12 (8-28) olarak bulundu. Ortanca takip süresi 41 ay idi. MM’de 3 senelik genel ve hastalıksız sağ kalım sırasıyla %75 ve %53 olarak, lenfomada 3 senelik genel ve hastalıksız sağ kalım sırasıyla %68 ve %64 olarak saptandı.
Sonuç: Ek hastalığa sahip olanların olmayanlara göre nötrofil engrafmanı sürelerinin anlamlı olarak daha uzun olduğu, MM’de immünglobulin G alt tipinin diğer tipler toplamına göre anlamlı olarak daha iyi nötrofil engrafman süresine sahip olduğu saptandı. MM’de 65 yaş ve altında olanların, 65 yaş üzerinde olan hastalara göre genel sağ kalımlarının anlamlı olarak daha iyi olduğu bulundu. Lenfomada erken evre hastalığın ileri evre hastalığa göre anlamlı olarak daha iyi sağ kalım sonuçları olduğu saptandı.
Objective: In our study, we aimed to evaluate the engraftment time and disease-free survival of patients with hematological malignancies who underwent autologous stem cell transplantation and to compare the results of our clinic with the literature. Method: A total of 113 autologous stem cell transplants performed in the Department of Hematology at Necmettin Erbakan University between December 2011 and December 2020 were retrospectively analyzed through patient record archive files and hospital information management system. IBM SPSS (v 20.0) was used to analyze the data. Results: There were 84 (74.3%) Multiple myeloma (MM), 19 (16.8%) non hodgkin lymphoma, 8 (7.1%) hodgkin lymphoma, 1 (0.9%) acute myeloid leukemia and 1 (0.9%) T-lymphoblastic lymphoma patient. 45.1% of the patients were female and 54.9% were male. The median neutrophil engraftment day was 11 (9-14) and platelet engraftment day was 12 (8-28). The median follow-up was 41 months. The 3-year overall and disease-free survival in MM was 75% and 53%, respectively. The 3-year overall and disease-free survival in lymphoma was 68% and 64%, respectively. Conclusions: It was determined that the duration of neutrophil engraftment was significantly longer in those with comorbidity, and the immunoglobulin G subtype in MM had a significantly better neutrophil engraftment time than the sum of other types. It was found that those aged 65 years and younger with MM had a significantly better overall survival than those over 65 years of age. It was found that early-stage disease in lymphoma had significantly better survival outcomes than advanced-stage disease.
Objective: In our study, we aimed to evaluate the engraftment time and disease-free survival of patients with hematological malignancies who underwent autologous stem cell transplantation and to compare the results of our clinic with the literature. Method: A total of 113 autologous stem cell transplants performed in the Department of Hematology at Necmettin Erbakan University between December 2011 and December 2020 were retrospectively analyzed through patient record archive files and hospital information management system. IBM SPSS (v 20.0) was used to analyze the data. Results: There were 84 (74.3%) Multiple myeloma (MM), 19 (16.8%) non hodgkin lymphoma, 8 (7.1%) hodgkin lymphoma, 1 (0.9%) acute myeloid leukemia and 1 (0.9%) T-lymphoblastic lymphoma patient. 45.1% of the patients were female and 54.9% were male. The median neutrophil engraftment day was 11 (9-14) and platelet engraftment day was 12 (8-28). The median follow-up was 41 months. The 3-year overall and disease-free survival in MM was 75% and 53%, respectively. The 3-year overall and disease-free survival in lymphoma was 68% and 64%, respectively. Conclusions: It was determined that the duration of neutrophil engraftment was significantly longer in those with comorbidity, and the immunoglobulin G subtype in MM had a significantly better neutrophil engraftment time than the sum of other types. It was found that those aged 65 years and younger with MM had a significantly better overall survival than those over 65 years of age. It was found that early-stage disease in lymphoma had significantly better survival outcomes than advanced-stage disease.
Açıklama
Anahtar Kelimeler
Otolog Kök Hücre Nakli, Multiple Myelom, Lenfoma, Engrafman, Sağ Kalım Süresi, Autologous Stem Cell Transplantation, Multiple Myeloma, Lymphoma, Engraftment, Survival Time
Kaynak
WoS Q Değeri
Scopus Q Değeri
Cilt
Sayı
Künye
Sayan, E. (2022). Çocuklarda santral sinir sisteminin inflamatuvar demiyelinizan hastalıklarının değerlendirilmesi. (Yayınlanmamış tıpta uzmanlık tezi) Necmettin Erbakan Üniversitesi, Meram Tıp Fakültesi Dahili Tıp Bilimleri Bölümü Çocuk Sağlığı ve Hastalıkları Anabilim Dalı, Konya.
